Synairgen plc
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein, which orchestrates the body's antiviral responses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the Unit… Read more
Synairgen plc (SYGGF) - Total Assets
Latest total assets as of December 2024: $7.82 Million USD
Based on the latest financial reports, Synairgen plc (SYGGF) holds total assets worth $7.82 Million USD as of December 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Synairgen plc - Total Assets Trend (2003–2024)
This chart illustrates how Synairgen plc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Synairgen plc - Asset Composition Analysis
Current Asset Composition (December 2024)
Synairgen plc's total assets of $7.82 Million consist of 97.4% current assets and 2.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 58.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $100.00K | 1.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2003–2024)
This chart illustrates how Synairgen plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Synairgen plc's current assets represent 97.4% of total assets in 2024, an increase from 76.5% in 2003.
- Cash Position: Cash and equivalents constituted 58.2% of total assets in 2024, up from 9.0% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2003.
- Asset Diversification: The largest asset category is intangible assets at 1.3% of total assets.
Synairgen plc Competitors by Total Assets
Key competitors of Synairgen plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Synairgen plc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Synairgen plc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Synairgen plc is currently not profitable relative to its asset base.
Synairgen plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.94 | 9.01 | 2.07 |
| Quick Ratio | 4.94 | 10.34 | 2.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.08 Million | $ 12.53 Million | $ 1.81 Million |
Synairgen plc - Advanced Valuation Insights
This section examines the relationship between Synairgen plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.00 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -45.0% |
| Total Assets | $7.82 Million |
| Market Capitalization | $11.03K USD |
Valuation Analysis
Below Book Valuation: The market values Synairgen plc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Synairgen plc's assets decreased by 45.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Synairgen plc (2003–2024)
The table below shows the annual total assets of Synairgen plc from 2003 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $7.82 Million | -45.00% |
| 2023-12-31 | $14.22 Million | -39.56% |
| 2022-12-31 | $23.53 Million | -47.29% |
| 2021-12-31 | $44.64 Million | -49.59% |
| 2020-12-31 | $88.55 Million | +2075.09% |
| 2019-12-31 | $4.07 Million | -40.17% |
| 2018-12-31 | $6.80 Million | -11.20% |
| 2017-12-31 | $7.66 Million | +38.18% |
| 2016-12-31 | $5.54 Million | -33.06% |
| 2015-12-31 | $8.28 Million | -16.59% |
| 2014-12-31 | $9.93 Million | +387.77% |
| 2013-12-31 | $2.04 Million | -46.52% |
| 2012-12-31 | $3.81 Million | -21.34% |
| 2010-12-31 | $4.84 Million | -36.05% |
| 2009-12-31 | $7.57 Million | -12.66% |
| 2008-12-31 | $8.67 Million | +81.60% |
| 2007-12-31 | $4.77 Million | -29.05% |
| 2006-12-31 | $6.73 Million | -17.79% |
| 2005-12-31 | $8.18 Million | -11.44% |
| 2004-12-31 | $9.24 Million | +1359.40% |
| 2003-12-31 | $633.00K | -- |